
Ruey-Meei Wu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4764021/publications.pdf Version: 2024-02-01



RUEV-MEELW/U

#	Article	IF	CITATIONS
1	VPS35 Mutations in Parkinson Disease. American Journal of Human Genetics, 2011, 89, 162-167.	6.2	747
2	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study. Lancet Neurology, The, 2011, 10, 898-908.	10.2	294
3	Minimal Detectable Change of the Timed "Up & Go―Test and the Dynamic Gait Index in People With Parkinson Disease. Physical Therapy, 2011, 91, 114-121.	2.4	275
4	DNAJC13 mutations in Parkinson disease. Human Molecular Genetics, 2014, 23, 1794-1801.	2.9	258
5	Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics, 2005, 6, 171-177.	1.4	237
6	Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Annals of Neurology, 2008, 64, 88-92.	5.3	207
7	Gene Therapy for Aromatic <scp>l</scp> -Amino Acid Decarboxylase Deficiency. Science Translational Medicine, 2012, 4, 134ra61.	12.4	195
8	Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism and Related Disorders, 2007, 13, 89-92.	2.2	191
9	Effects of Virtual Reality–Augmented Balance Training on Sensory Organization and Attentional Demand for Postural Control in People With Parkinson Disease: A Randomized Controlled Trial. Physical Therapy, 2011, 91, 862-874.	2.4	157
10	<i>LRRK2</i> G2019S Mutation Induces Dendrite Degeneration through Mislocalization and Phosphorylation of Tau by Recruiting Autoactivated GSK3β. Journal of Neuroscience, 2010, 30, 13138-13149.	3.6	153
11	Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. European Journal of Pharmacology, 1993, 243, 241-247.	3.5	134
12	Home-based virtual reality balance training and conventional balance training in Parkinson's disease: A randomized controlled trial. Journal of the Formosan Medical Association, 2016, 115, 734-743.	1.7	123
13	Overexpression of Heme Oxygenase-1 Protects Dopaminergic Neurons against 1-Methyl-4-Phenylpyridinium-Induced Neurotoxicity. Molecular Pharmacology, 2008, 74, 1564-1575.	2.3	122
14	Discontinuation of statin therapy associates with Parkinson disease. Neurology, 2013, 81, 410-416.	1.1	110
15	Multiple <i>LRRK2</i> variants modulate risk of Parkinson disease: a Chinese multicenter study. Human Mutation, 2010, 31, n/a-n/a.	2.5	106
16	Risk of Parkinson's disease following severe constipation: A nationwide population-based cohort study. Parkinsonism and Related Disorders, 2014, 20, 1371-1375.	2.2	97
17	PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions. Molecular Cell, 2018, 69, 744-756.e6.	9.7	88
18	Parkin Mutations and Early-Onset Parkinsonism in a Taiwanese Cohort. Archives of Neurology, 2005, 62, 82.	4.5	84

#	Article	IF	CITATIONS
19	Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson's disease. Clinica Chimica Acta, 2007, 378, 136-141.	1.1	79
20	Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease. Movement Disorders, 2007, 22, 550-555.	3.9	75
21	Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort Study. PLoS ONE, 2014, 9, e98961.	2.5	74
22	<i>PLA2G6</i> mutations in PARK14â€linked youngâ€onset parkinsonism and sporadic Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 183-191.	1.7	71
23	Biomarkers of cognitive decline in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 431-443.	2.2	71
24	A clinical and genetic study of earlyâ€onset and familial parkinsonism in taiwan: An integrated approach combining gene dosage analysis and nextâ€generation sequencing. Movement Disorders, 2019, 34, 506-515.	3.9	71
25	Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. Journal of Neurology, 2007, 254, 501-507.	3.6	68
26	The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. Parkinsonism and Related Disorders, 2007, 13, 246-249.	2.2	62
27	Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: A nationwide, population-based study. Journal of the Formosan Medical Association, 2016, 115, 531-538.	1.7	56
28	Antioxidant Mechanism and Protection of Nigral Neurons Against MPP ⁺ Toxicity by Deprenyl (Selegiline). Annals of the New York Academy of Sciences, 1994, 738, 214-221.	3.8	55
29	Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis. PLoS ONE, 2013, 8, e69190.	2.5	55
30	Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria. Human Genetics, 2011, 130, 817-827.	3.8	54
31	LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. Journal of Biomedical Science, 2008, 15, 661-7.	7.0	50
32	Lrrk regulates the dynamic profile of dendritic Golgi outposts through the golgin Lava lamp. Journal of Cell Biology, 2015, 210, 471-483.	5.2	46
33	Lovastatin protects neurite degeneration in <i>LRRK2-G2019S</i> parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3Î ² activity. Human Molecular Genetics, 2016, 25, 1965-1978.	2.9	45
34	The role of noncoding RNAs in Parkinson's disease: biomarkers and associations with pathogenic pathways. Journal of Biomedical Science, 2021, 28, 78.	7.0	45
35	Clinical,18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism andparkin gene mutations. Movement Disorders, 2002, 17, 670-675.	3.9	44
36	Advanced Theory of Mind in patients at early stage of Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 21-24.	2.2	42

#	Article	IF	CITATIONS
37	Detecting Mild Cognitive Deficits in <scp>P</scp> arkinson's <scp>D</scp> isease: <scp>C</scp> omparison of <scp>N</scp> europsychological <scp>T</scp> ests. Movement Disorders, 2018, 33, 1750-1759.	3.9	42
38	Suppression of Hydroxyl Radical Formation and Protection of Nigral Neurons by l-Deprenyl (Selegiline). Annals of the New York Academy of Sciences, 1996, 786, 379-390.	3.8	41
39	Effect of MAOâ€B Inhibitors on MPP ⁺ Toxicity <i>in Vivo</i> . Annals of the New York Academy of Sciences, 2000, 899, 255-261.	3.8	40
40	Neuropsychological profile in patients with early stage of Parkinson's disease in Taiwan. Parkinsonism and Related Disorders, 2012, 18, 1067-1072.	2.2	40
41	Lrrk2 S1647T and BDNF V66M interact with environmental factors to increase risk of Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 84-88.	2.2	38
42	Motion analysis of axial rotation and gait stability during turning in people with Parkinson's disease. Gait and Posture, 2016, 44, 83-88.	1.4	37
43	Mitochondrial <i>UQCRC1</i> mutations cause autosomal dominant parkinsonism with polyneuropathy. Brain, 2020, 143, 3352-3373.	7.6	37
44	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiology of Aging, 2014, 35, 266.e5-266.e14.	3.1	36
45	<i>COQ2</i> gene variants associate with cerebellar subtype of multiple system atrophy in Chinese. Movement Disorders, 2015, 30, 436-437.	3.9	36
46	Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism and Related Disorders, 2009, 15, 466-467.	2.2	31
47	Vitamin D receptor genetic variants and Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2014, 35, 1212.e11-1212.e13.	3.1	31
48	The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in Taiwan. Neuropsychiatric Disease and Treatment, 2015, 11, 2865.	2.2	31
49	Populationâ€specific frequencies for <i>LRRK2</i> susceptibility variants in the genetic epidemiology of Parkinson's disease (GEOâ€PD) consortium. Movement Disorders, 2013, 28, 1740-1744.	3.9	30
50	O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer, 2010, 68, 484-490.	2.0	29
51	Cross ultural Differences of the Nonâ€Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society–Unified Parkinson's Disease Rating Scale. Movement Disorders Clinical Practice, 2017, 4, 68-77.	1.5	29
52	LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review. Journal of Biomedical Science, 2018, 25, 52.	7.0	29
53	BST1 rs11724635 interacts with environmental factors to increase the risk of Parkinson's disease in a Taiwanese population. Parkinsonism and Related Disorders, 2014, 20, 280-283.	2.2	28
54	Lack of mutations in DJ-1 in a cohort of Taiwanese ethnic Chinese with early-onset parkinsonism. Movement Disorders, 2004, 19, 1065-1069.	3.9	27

#	Article	IF	CITATIONS
55	Aldehyde dehydrogenase 2 is associated with cognitive functions in patients with Parkinson's disease. Scientific Reports, 2016, 6, 30424.	3.3	27
56	DCTN1 p.K56R in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 28, 56-61.	2.2	27
57	Acoustic and perceptual speech characteristics of native Mandarin speakers with Parkinson's disease. Journal of the Acoustical Society of America, 2017, 141, EL293-EL299.	1.1	27
58	Lrrk2 R1628P in nonâ€Chinese Asian races. Annals of Neurology, 2008, 64, 472-473.	5.3	26
59	Test-retest reliability and minimal detectable change of the Beck Depression Inventory and the Taiwan Geriatric Depression Scale in patients with Parkinson's disease. PLoS ONE, 2017, 12, e0184823.	2.5	26
60	A novel neuropsychiatric phenotype of KCNJ2 mutation in one Taiwanese family with Andersen–Tawil syndrome. Journal of Human Genetics, 2010, 55, 186-188.	2.3	25
61	Genotype–phenotype correlates in Taiwanese patients with earlyâ€onset recessive parkinsonism. Movement Disorders, 2009, 24, 104-108.	3.9	24
62	Social brain dysfunctions in patients with Parkinson's disease: a review of theory of mind studies. Translational Neurodegeneration, 2013, 2, 7.	8.0	23
63	A <scp>Doubleâ€Blind</scp> , Randomized, Controlled Trial of Lovastatin in <scp>Earlyâ€Stage</scp> Parkinson's Disease. Movement Disorders, 2021, 36, 1229-1237.	3.9	22
64	Pathophysiology of Small-Fiber Sensory System in Parkinson's Disease. Medicine (United States), 2016, 95, e3058.	1.0	21
65	Meige Syndrome Relieved by Bilateral Pallidal Stimulation With Cycling Mode. Neurosurgery, 2011, 69, E1333-E1337.	1.1	20
66	Increase of oxidative stress by a novel PINK1 mutation, P209A. Free Radical Biology and Medicine, 2013, 58, 160-169.	2.9	19
67	Memory for gist and detail information in patients with Parkinson's disease. BMJ Open, 2015, 5, e009795.	1.9	19
68	Feelingâ€ofâ€knowing in episodic memory in patients with Parkinson's disease with various motor symptoms. Movement Disorders, 2010, 25, 1034-1039.	3.9	18
69	Mutational analysis of FBXO7 gene in Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2013, 34, 1713.e1-1713.e4.	3.1	18
70	Alpha-Synuclein and Cognitive Decline in Parkinson Disease. Life, 2021, 11, 1239.	2.4	18
71	<i>GCH1</i> in earlyâ€onset Parkinson's disease. Movement Disorders, 2009, 24, 2070-2075.	3.9	17
72	Non-synonymous GIGYF2 variants in Parkinson's disease from two Asian populations. Human Genetics, 2009, 126, 425-430.	3.8	17

#	Article	IF	CITATIONS
73	Clinical heterogeneity of LRRK2 p.I2012T mutation. Parkinsonism and Related Disorders, 2016, 33, 36-43.	2.2	17
74	Effect of ALDH2 on Sleep Disturbances in Patients with Parkinson's Disease. Scientific Reports, 2019, 9, 18950.	3.3	17
75	STX6 rs1411478 is not associated with increased risk of Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 563-565.	2.2	16
76	Lack of CHCHD2 mutations in Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2016, 38, 218.e1-218.e2.	3.1	16
77	Analysis of GWAS-linked variants in multiple system atrophy. Neurobiology of Aging, 2018, 67, 201.e1-201.e4.	3.1	16
78	Lack of C9orf72 Repeat Expansion in Taiwanese Patients with Mixed Neurodegenerative Disorders. Frontiers in Neurology, 2014, 5, 59.	2.4	15
79	The impact of nocturnal disturbances on daily quality of life in patients with Parkinson's disease. Neuropsychiatric Disease and Treatment, 2015, 11, 2005.	2.2	15
80	Reaffirmation of GAK, but not HLAâ€DRA, as a Parkinson's disease susceptibility gene in a Taiwanese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 841-846.	1.7	14
81	Application of the University of Pennsylvania Smell Identification Test (Traditional Chinese Version) for Detecting Olfactory Deficits in Early Parkinson's Disease in a Taiwanese Cohort. Journal of Parkinson's Disease, 2014, 4, 175-180.	2.8	14
82	Mutational analysis of SYNJ1 gene (PARK20) in Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2015, 36, 2905.e7-2905.e8.	3.1	13
83	Immediate Effects of Clock-Turn Strategy on the Pattern and Performance of Narrow Turning in Persons With Parkinson Disease. Journal of Neurologic Physical Therapy, 2016, 40, 249-256.	1.4	13
84	Predictors of road crossing safety in pedestrians with Parkinson's disease. Accident Analysis and Prevention, 2013, 51, 202-207.	5.7	11
85	RIT2 variant is not associated with Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2013, 34, 2236.e1-2236.e3.	3.1	11
86	Improving Dual-Task Control With a Posture-Second Strategy in Early-Stage Parkinson Disease. Archives of Physical Medicine and Rehabilitation, 2018, 99, 1540-1546.e2.	0.9	11
87	Dynamic Trk and G Protein Signalings Regulate Dopaminergic Neurodifferentiation in Human Trophoblast Stem Cells. PLoS ONE, 2015, 10, e0143852.	2.5	10
88	Effects of rhythmic auditory cueing on stepping in place in patients with Parkinson's disease. Medicine (United States), 2019, 98, e17874.	1.0	10
89	Amantadine treatment and delayed onset of levodopaâ€induced dyskinesia in patients with early Parkinson's disease. European Journal of Neurology, 2022, 29, 1044-1055.	3.3	10
90	Association of pyridoxal kinase and Parkinson disease. Annals of Neurology, 2010, 67, 409-411.	5.3	9

Ruey-Meei Wu

#	Article	IF	CITATIONS
91	Rapid screening of <i>ATP13A2</i> variant with highâ€resolution melting analysis. Movement Disorders, 2010, 25, 2434-2437.	3.9	9
92	LRRK2 Parkinson's disease: from animal models to cellular mechanisms. Reviews in the Neurosciences, 2011, 22, 411-8.	2.9	9
93	Lack of <i>TMEM230</i> mutations in patients with familial and sporadic Parkinson's disease in a Taiwanese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 751-756.	1.7	9
94	Lack of RAB39B mutations in early-onset and familial Parkinson's disease in a Taiwanese cohort. Neurobiology of Aging, 2017, 50, 169.e3-169.e4.	3.1	9
95	Interactions of COMT and ALDH2 Genetic Polymorphisms on Symptoms of Parkinson's Disease. Brain Sciences, 2021, 11, 361.	2.3	9
96	Lack of mutations in spinocerebellar ataxia type 2 and 3 genes in a Taiwanese (ethnic Chinese) cohort of familial and early-onset parkinsonism. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 434-438.	1.7	8
97	Neurocysticercosis Presenting with Epilepsia Partialis Continua: A Clinicopathologic Report and Literature Review. Journal of the Formosan Medical Association, 2008, 107, 576-581.	1.7	8
98	Analysis of PArkin Co-Regulated Gene in a Taiwanese–Ethnic Chinese cohort with early-onset Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 417-421.	2.2	8
99	Acoustic and Perceptual Consequences of Speech Cues for Mandarin Speakers With Parkinson's Disease. American Journal of Speech-Language Pathology, 2019, 28, 521-535.	1.8	8
100	Ectopic Pregnancy-Derived Human Trophoblastic Stem Cells Regenerate Dopaminergic Nigrostriatal Pathway to Treat Parkinsonian Rats. PLoS ONE, 2012, 7, e52491.	2.5	8
101	Longâ€ŧerm efficacy of bilateral subthalamic deep brain stimulation in the parkinsonism of SCA 3: A rare case report. European Journal of Neurology, 2022, 29, 2544-2547.	3.3	8
102	National Trends of Antiparkinsonism Treatment in Taiwan: 2004–2011. Parkinson's Disease, 2016, 2016, 1-8.	1.1	7
103	Advanced brain aging in multiple system atrophy compared to Parkinson's disease. NeuroImage: Clinical, 2022, 34, 102997.	2.7	7
104	Mutational Analysis of Angiogenin Gene in Parkinson's Disease. PLoS ONE, 2014, 9, e112661.	2.5	6
105	The Effects of Task Prioritization on Dual-Tasking Postural Control in Patients With Parkinson Disease Who Have Different Postural Impairments. Archives of Physical Medicine and Rehabilitation, 2020, 101, 1212-1219.	0.9	6
106	Psychotic-affective symptoms and multiple system atrophy expand phenotypes of spinocerebellar ataxia type 2. BMJ Case Reports, 2012, 2012, bcr1020115061-bcr1020115061.	0.5	6
107	Lack of PTRHD1 mutation in patients with young-onset and familial Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2021, 100, 118.e15-118.e16.	3.1	5
108	Effects of task prioritization on a postural-motor task in early-stage Parkinson's disease: EEG connectivity and clinical implication. GeroScience, 2022, 44, 2061-2075.	4.6	5

#	Article	IF	CITATIONS
109	Common variants in Parkinson's disease. Movement Disorders, 2007, 22, 899-900.	3.9	4
110	Focal brain glucose hypermetabolism in myoclonus-dystonia syndrome caused by an epsilon-sarcoglycan gene mutation. Parkinsonism and Related Disorders, 2009, 15, 614-616.	2.2	4
111	Mystery Case: Hemiballism in a patient with parietal lobe infarction. Neurology, 2013, 80, e22.	1.1	4
112	COQ2 p.V393A variant, rs148156462, is not associated with Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2015, 36, 546.e17-546.e18.	3.1	4
113	Control of the Motions of the Body's Center of Mass and End-Points of the Lower Limbs in Patients with Mild Parkinson's Disease During Obstacle-Crossing. Journal of Medical and Biological Engineering, 2018, 38, 534-543.	1.8	4
114	Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition. Current Medicinal Chemistry - Central Nervous System Agents, 2004, 4, 255-267.	0.5	4
115	CPP antagonizes hypoxia-induced changes in dopamine metabolism in the striatum of newborn rat. Neuroscience Research, 1999, 35, 347-350.	1.9	3
116	Lack of evidence for association of a parkin promoter polymorphism with early-onset Parkinson's disease in a Chinese population. Parkinsonism and Related Disorders, 2009, 15, 149-152.	2.2	3
117	VPS35 Mutations in Parkinson Disease. American Journal of Human Genetics, 2011, 89, 347.	6.2	3
118	Parkinson disease risk variants in East Asian populations. Nature Reviews Neurology, 2020, 16, 461-462.	10.1	3
119	Updates on the Genetics of Parkinson's Disease: Clinical Implications and Future Treatment. Acta Neurologica Taiwanica, 2021, 30(3), 83-93.	0.3	3
120	Evaluation of l-DOPA biotransformation during repeated l-DOPA infusion into the striatum in freely-moving young and old rats. Developmental Brain Research, 2000, 121, 123-131.	1.7	2
121	Attentional Resource Associated With Visual Feedback on a Postural Dual Task in Parkinson's Disease. Neurorehabilitation and Neural Repair, 2020, 34, 891-903.	2.9	2
122	Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation: A Novel DARS2 Mutation and Intraâ€Familial Heterogeneity. Movement Disorders Clinical Practice, 2021, 8, 1116-1122.	1.5	2
123	The Effects of Intensive Voice Treatment in Mandarin Speakers With Parkinson's Disease: Acoustic and Perceptual Findings. American Journal of Speech-Language Pathology, 2022, 31, 1354-1367.	1.8	2
124	<scp><i>COQ2</i></scp> and <scp><i>SNCA</i></scp> polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition. European Journal of Neurology, 2022, 29, 2956-2966.	3.3	2
125	Pulsed Wave Doppler Ultrasound Is Useful to Assess Vasomotor Response in Patients with Multiple System Atrophy and Well Correlated with Tilt Table Study. Scientific World Journal, The, 2012, 2012, 1-8.	2.1	1
126	Does cigarette smoking do nothing but harm?. Neurology, 2018, 90, 307-308.	1.1	1

#	Article	IF	CITATIONS
127	PDE8B mutation is not associated with Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2018, 71, 265.e15-265.e16.	3.1	1
128	Genetic analysis of PODXL gene in patients with familial and young-onset Parkinson's disease in a Taiwanese population. Neurobiology of Aging, 2019, 84, 235.e9-235.e10.	3.1	1
129	Modified Frameless Stereotactic System for Intracerebral Delivery of Viral Vector in Young Children. Operative Neurosurgery, 2019, 18, 166-174.	0.8	1
130	Neurodegeneration with brain iron accumulation presenting motor trick and impaired motor cortical plasticity. Clinical Neurology and Neurosurgery, 2016, 141, 95-97.	1.4	0
131	Reply: UQCRC1 variants in Parkinson's disease: a large cohort study in Chinese mainland population. Brain, 2021, 144, e55-e55.	7.6	Ο
132	Attentional focus effect on dual-task walking in Parkinson's disease with and without freezing of gait. GeroScience, 0, , .	4.6	0